REVXF
+0.0 · +0.00%
USD · OTCGREY

Revenio Group Oyj(REVXF) Stock Analysis | Healthcare

USD --+0.00%
Reward55Moderate
Risk45Moderate
75%Data
Strong 16% profit margin
Quality Compounder
Market Cap:701.50M
ⓘ
Reward Rating
55
Moderate
Reward Assessment
75% data coverage
Bottom 50% of stocksView factors
ⓘ
Risk Rating
45
Moderate
Risk Assessment

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

Educational tool only · More
Limited data coverage
We don't have enough public data on REVXF to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
New listing — limited trading history
Fundamental and analyst data are available for REVXF, but momentum and volatility metrics will develop as more trading history accumulates (0 trading sessions so far).
Not available yet for this stock
The overview tab requires data we don't have for this stock yet. The price chart is the most reliable view we have — try the Chart tab.
Earnings Ex-dividend

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

What is Revenio Group Oyj?

Revenio Group Oyj, provides ophthalmological devices and software solutions for the diagnosis of glaucoma, macular degeneration, and diabetic retinopathy in Finland, the United States, and internationally.

REVXF · Verdict

Solid reward · moderate risk

REVXF stands out on profitability and cash flow, but watch the volatility signal.

Based on 88% data coverage

REVXF · Verdict

What’s working & what to watch

Strengths 3

  • Profitability95/100

    16% net margin · 16% ROE

  • Cash flow94/100

    24% free-cash-flow margin

  • Balance sheet88/100

    Current ratio 2.05

Watchouts 2

  • Volatility35/100

    Below average

  • Growth40/100

    Rev +4.2% CAGR · earnings -7.2%

Model-based scoring. For information only — not financial advice.

What is Revenio Group Oyj?

Revenio Group Oyj, provides ophthalmological devices and software solutions for the diagnosis of glaucoma, macular degeneration, and diabetic retinopathy in Finland, the United States, and internationally. The company offers iCare IC100, ST500, and IC200 tonometers; iCare HOME2, a tonometer to measure eye pressure; iCare Probes that are accessories of iCare tonometer for measuring intraocular pressure (IOP); iCare TONOVET Pro, a tonometer designed for use in surgical or emergency settings; and iCare TONOVET Plus tonometer, which is used for measuring IOP on animal patients by general veterinary practitioners, veterinary ophthalmologists and other veterinary medical personnel. The company is listed on the OTCGREY in USA, operating in the Healthcare sector, with a market capitalisation of 701.50M, and a P/E ratio of 32.1x.

Financial Highlights

Investment Breakdown

Growth
Moderate growth momentum — positive trajectory without breakout acceleration.
Profitability
Strong margins and consistent earnings support financial stability.
Risk
Risk profile appears balanced versus broad market conditions.
Valuation
Premium valuation reflects strong growth expectations already priced in.

OpenBook Logo Analysis

Reward: Moderate (55)

The scoring profile indicates moderate reward potential, with profitability and momentum as the leading contributors. Risk indicators are moderate, consistent with typical market exposure.

For informational purposes only. Not financial advice.

Similar stocks to compare

A short list of Medical Devices names that are close enough in size to make side-by-side comparison useful.

Company Information
SectorHealthcare
IndustryMedical Devices
Market Cap701.50M
P/E Ratio32.0513
Dividend YieldN/A
Beta1.253
Insider Activity
12M windowNo data
No insider activity data available for this ticker.